MX2018003313A - Celulas asesinas naturales modificadas con propiedades anti-fuctacticas y sus usos. - Google Patents

Celulas asesinas naturales modificadas con propiedades anti-fuctacticas y sus usos.

Info

Publication number
MX2018003313A
MX2018003313A MX2018003313A MX2018003313A MX2018003313A MX 2018003313 A MX2018003313 A MX 2018003313A MX 2018003313 A MX2018003313 A MX 2018003313A MX 2018003313 A MX2018003313 A MX 2018003313A MX 2018003313 A MX2018003313 A MX 2018003313A
Authority
MX
Mexico
Prior art keywords
natural killer
modified natural
killer cells
fugetactic properties
fugetactic
Prior art date
Application number
MX2018003313A
Other languages
English (en)
Inventor
C Poznansky Mark
Vianello Fabrizio
Original Assignee
The General Hospital Corp Dba Massacsetts General Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The General Hospital Corp Dba Massacsetts General Hospital filed Critical The General Hospital Corp Dba Massacsetts General Hospital
Publication of MX2018003313A publication Critical patent/MX2018003313A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

La presente invención proporciona métodos ex vivo para hacer composiciones de células asesinas naturales modificadas que tienen propiedades generales anti-fuctácticas para el tratamiento efectivo y eficiente de tumores o cánceres en un paciente y composiciones y uso de las mismas.
MX2018003313A 2015-09-18 2016-09-16 Celulas asesinas naturales modificadas con propiedades anti-fuctacticas y sus usos. MX2018003313A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562220857P 2015-09-18 2015-09-18
US201662303367P 2016-03-03 2016-03-03
US201662303364P 2016-03-03 2016-03-03
PCT/US2016/052333 WO2017049228A1 (en) 2015-09-18 2016-09-16 Modified natural killer cells having anti-fugetactic properties and uses thereof

Publications (1)

Publication Number Publication Date
MX2018003313A true MX2018003313A (es) 2018-11-09

Family

ID=57121512

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003313A MX2018003313A (es) 2015-09-18 2016-09-16 Celulas asesinas naturales modificadas con propiedades anti-fuctacticas y sus usos.

Country Status (11)

Country Link
US (1) US20170100433A1 (es)
EP (1) EP3350317A1 (es)
JP (2) JP7098518B2 (es)
CN (1) CN108368485A (es)
AU (1) AU2016324293A1 (es)
CA (1) CA2999090A1 (es)
HK (1) HK1259030A1 (es)
IL (1) IL258193A (es)
MX (1) MX2018003313A (es)
TW (1) TW201718851A (es)
WO (1) WO2017049228A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112513079A (zh) * 2018-03-13 2021-03-16 拉巴斯大学医院生物医学研究基金会 用于癌症免疫疗法的联合激活和扩增的自然杀伤细胞的抗cxcr4抗体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0906954A1 (en) * 1997-09-29 1999-04-07 Applied Research Systems ARS Holding N.V. Amino-terminal truncated c-c chemokines as chemokine antagonist
US6171590B1 (en) * 1998-09-30 2001-01-09 Corixa Corporation Chemokine receptor peptide for inducing an immune response
WO2004053165A1 (en) * 2002-12-06 2004-06-24 The General Hospital Corporation Methods and compositions relating to gradient exposed cells
WO2006137934A2 (en) * 2004-11-05 2006-12-28 The General Hospital Corporation Purposeful movement of human migratory cells away from an agent source
CN102046199A (zh) * 2008-03-20 2011-05-04 卡罗勒斯治疗公司 使用抗mif抗体的治疗方法
KR20220053695A (ko) 2010-07-13 2022-04-29 셀룰래리티 인코포레이티드 천연 킬러 세포의 생성 방법
US20140120555A1 (en) * 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
EP3030322A2 (en) * 2013-08-05 2016-06-15 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy

Also Published As

Publication number Publication date
CA2999090A1 (en) 2017-03-23
JP2022130602A (ja) 2022-09-06
US20170100433A1 (en) 2017-04-13
IL258193A (en) 2018-05-31
JP2018533915A (ja) 2018-11-22
WO2017049228A1 (en) 2017-03-23
CN108368485A (zh) 2018-08-03
AU2016324293A1 (en) 2018-04-26
JP7098518B2 (ja) 2022-07-11
EP3350317A1 (en) 2018-07-25
HK1259030A1 (zh) 2019-11-22
TW201718851A (zh) 2017-06-01

Similar Documents

Publication Publication Date Title
PH12020551923A1 (en) Methods and compositions for treating cancer
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
GB2557123A (en) Modified cells and methods of therapy
NZ737471A (en) Hydrophilic linkers for conjugation
TW201611847A (en) Compounds and compositions for treating EGFR expressing tumors
WO2017096309A8 (en) Methods of treatment of malignancies
MD4733B1 (ro) Anticorpi anti-TIGIT
MX2014011134A (es) Compuestos de carbamato y preparacion y uso de los mismos.
MY187540A (en) Compounds active towards bromodomains
MX370807B (es) Anticuerpos que se unen a axl.
SG10201808835QA (en) Anti-siglec-8 antibodies and methods of use thereof
WO2017079570A3 (en) Splise-switching oligonucleotides and methods of use
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
MX2015007185A (es) Uso de eribulina en el tratamiento de cancer de pecho.
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
EP3242688A4 (en) Cox-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers
MX2016016756A (es) Terapia con células madre en patologías endometriales.
HUE047540T2 (hu) Javított allogén dendritikus sejtek rák kezelésében történõ alkalmazásra
MX2019015676A (es) Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
PH12016501838A1 (en) Compounds and their methods of use
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX2023007706A (es) Nanoparticulas para su uso como vacuna terapeutica.
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.
NZ713129A (en) Oxprenolol compositions for treating cancer